Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance

Table 6 Changes in laboratory values from baseline to week 12

Measure	n	Mean	SD
GPT (U/L)
Baseline	376	25.14	21.548
Week 12	109	27.33	20.624
Mean change	93	5.381	21.705
GOT (U/L)
Baseline	363	22.19	12.715
Week 12	108	24.39	12.565
Mean change	92	0.96	16.625
Serum creatinine (μmol/L)
Baseline	370	65.86	16.383
Week 12	106	69.26	14.695
Mean change	90	1.21	10.854
Fasting blood glucose (mmol/L)
Baseline	368	5.478	1.536
Week 12	101	5.451	1.5486
Mean change	84	-0.162	1.4467
Total cholesterol (mmol/L)
Baseline	363	4.501	1.0389
Week 12	101	4.551	1.0888
Mean change	83	-0.079	1.1075
Triglycerides (mmol/L)
Baseline	362	1.589	1.3002
Week 12	101	1.655	0.8413
Mean change	82	-0.207	1.3234
HDL cholesterol (mmol/L)
Baseline	359	1.287	0.365
Week 12	99	1.308	0.3959
Mean change	82	0.073	0.415
LDL cholesterol (mmol/L)
Baseline	344	2.694	0.8467
Week 12	90	2.746	0.7907
Mean change	73	-0.086	0.7312
QTc interval (ms)
Baseline	280	415.6	93.41
Week 12	71	402	29.32
Mean change	57	-0.2	35.76

¹P < 0.05.

GPT: Glutamic pyruvic transaminase; GOT: Glutamic oxaloacetic transaminase; HbA1c: Glycosylated hemoglobin; LDL: Low-density lipoprotein; HDL: High density lipoprotein.